Black Raspberry Inhibits Angiogenesis in Human Carcinoid Cancer Tumor Assays
BerriProducts LLC, an Oregon-based supplier of premium quality black raspberry products shares news from the recently-attended Berry Health Benefits Symposium on angiogenesis inhibition with an in vitro test on human carcinoid cancer cells
Charlotte, North Carolina (PRWEB) June 25, 2013
Dr. Eugene Woltering, Section Chief of Surgical Endocrinology at the Louisiana State University Health Sciences Center in New Orleans presented some results of his work on neuroendocrine tumors (NETS). Dr. Woltering’s team developed an in vitro assay to measure tumor-derived angiogenesis in individual patients’ tumors. Dr. Woltering presented the results at the Berry Health Benefits Symposium in Charlotte, North Carolina on June 18, 2013.
The proprietary assay developed at Louisiana State University enables the in vitro testing of angiogenesis inhibitors on an individual’s specific tumor. This allows for better screening and selection of the most effective and potent treatment options. Dr. Woltering and his team have also compared a wide variety of treatments that are thought to potentially help reduce or reverse cancerous tumor growth.
Initial results indicate a significant reduction in the angiogenic response of many tumor samples with a simple water based black raspberry extract made from black raspberry powder. In addition, when relatively low-cost prescription drugs are combined with the black raspberry extract, angiogenesis was in some cases reduced more than seen with many FDA-approved antiangiogenic drugs.
It is important to note that these results are based on in vitro experiments done in the lab, not in individual patients. More work is required understand the potential benefits of the consumption of a black raspberry extract, and how it would affect tumors in the human body. To do this, Dr. Woltering and his colleagues at LSU have recently requested funding for a phase III clinical trial of a black raspberry extract in patients with neuroendocrine tumors. The trial would study black raspberry extract in alone and in combination with more conventional drugs in midgut neuroendocrine tumor patients, and also seek to understand if black raspberries in some form are a viable treatment option for patients whose tumor cells exhibit reduced angiogenesis in the in vitro assay.
Freeze-dried black raspberry powder continues to be used in numerous clinical trials and has great potential as a functional food for wellness. Black raspberries, not to be confused with blackberries, are almost exclusively grown in Oregon, on the west coast of the United States. They have been studied extensively because of their high concentration of phytonutrients and antioxidants.
About BerriProducts LLC:
Located in the heart of one of the premier berry growing regions in the world in Northwestern Oregon, they have been providing high-quality specialty black raspberry products for scientific research, and direct to consumers since 2009 through http://www.berrihealth.com. They partner with select Oregon farm partners to produce the highest quality black raspberry products. By focusing on partnering with exceptional farms, controlling careful and timely harvesting, quality after-harvest processing, and using advanced packaging technology they insure their extensively tested products are phytonutrient rich year in and year out and that they stay that way until consumed.
BerriProducts’ founding partners includes Gary Stoner, PhD, Professor of Medicine at the Medical College of Wisconsin Division of Hematology and Oncology and Professor Emeritus of the Ohio State University James Comprehensive Cancer Center. Dr. Stoner has been researching berries, particularly black raspberries, and their beneficial health effects for over twelve years.
More details on BerriProducts LLC and black raspberries can be found at http://www.berrihealth.com.
For the original version on PRWeb visit: http://www.prweb.com/releases/2013/6/prweb10869383.htm